RATIONALE AND OBJECTIVES: To assess the prostate T2 value as a predictor of malignancy on two different 3T scanners.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: Eighty-three pre-prostatectomy multiparametric MRIs were retrospectively evaluated [67 obtained on a General Electric MRI (scanner 1) and 16 on a Philips MRI (scanner 2)]. After correlation with prostatectomy specimens, readers measured the T2 value of regions-of-interest categorized as "cancers", "false positive lesions", or "normal tissue".
RESULTS: On scanner 1, in PZ, cancers had significantly lower T2 values than false positive lesions (P=0.02) and normal tissue (P=2×10-9). Gleason≥6 cancers had similar T2 values than false positive lesions and significantly higher T2 values than Gleason ≥7 cancers (P=0.009). T2 values corresponding to a 25% and 75% risk of Gleason ≥7 malignancy were respectively 132ms (95% CI: 129-135ms) and 77ms (95% CI: 74-81ms). In TZ, cancers had significantly lower T2 values than normal tissue (P=0.008), but not than false positive findings. Mean T2 values measured on scanner 2 were not significantly different than those measured on scanner 1 for all tissue classes.
CONCLUSION: All tested tissue classes had similar mean T2 values on both scanners. In PZ, the T2 value was a significant predictor of Gleason ≥7 cancers.
Hoang Dinh A, Souchon R, Melodelima C, Bratan F, Mège-Lechevallier F, Colombel M, Rouvière O. Are you the author?
Inserm, U1032, LabTau, Lyon 69003, France; Université Joseph-Fourier, laboratoire d'écologie Alpine, BP 53, Grenoble 38041, France; CNRS, UMR 5553, BP 53, Grenoble 38041, France; Hospices civils de Lyon, department of urinary and vascular radiology, hôpital Édouard-Herriot, Lyon 69437, France; Université de Lyon, Lyon 69003, France; Université Lyon 1, faculté de médecine Lyon Est, Lyon 69003, France; Hospices civils de Lyon, department of pathology, hôpital Édouard-Herriot, Lyon, 69437, France; Université de Lyon, Lyon 69003, France; Hospices civils de Lyon, department of urology, hôpital Édouard-Herriot, Lyon, 69437, France; Université de Lyon, Lyon 69003, France.
Reference: Diagn Interv Imaging. 2014 Dec 23. pii: S2211-5684(14)00316-7.